卡伯戈林在非照射的患有巨的患者中的有效性:一项多中心队列研究
Sandrine A Urwyler1,2,3, Irene Samperi1,2,3, Kirstie Lithgow1,2,3
1Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, UK.
European journal of endocrinology
|January 17, 2024
概括
卡伯戈林单一疗法在约三分之一的壮病患者中使IGF-1正常化,而与索马托斯塔丁受体连接体的联合疗法则显示出较低的疗效. 需要进一步的研究,以了解这些结果在非辐射患者.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 巨症是一种罕见的内分泌疾病,由多余的生长激素 (GH) 引起.
- 治疗的目的是使GH和胰岛素样生长因子1 (IGF-1) 的水平正常化.
- 卡伯戈林和体静止素受体连接体 (SRLs) 用于巨病的管理.
研究的目的:
- 为了评估卡伯戈林单独治疗的疗效或作为SRLs的附加剂,在非辐射壮病患者中.
- 评估生化控制 (IGF-1和GH水平) 和瘤缩.
主要方法:
- 多中心,回顾性队列研究,涉及四个英国下垂体中心.
- 对69名卡伯戈林单独治疗的患者和26名SRL加卡伯戈林治疗的患者的临床,实验室和成像数据的分析.
- 生物化学标准包括IGF-1和GH水平在1mcg/L以下的正常化.
主要成果:
- 在31.9%的患者中,卡伯戈林单一治疗使IGF-1正常化,在GH + 益生菌共分泌瘤中,这一比例更高.
- 联合SRL和卡伯戈林治疗在23.1%的患者中实现了正常的IGF-1.
- 在用卡伯戈林单疗治疗的GH分泌腺瘤中,观察到29.4%的瘤缩小.
结论:
- 卡伯戈林单一治疗有效地使IGF-1在约三分之一的非辐射壮病患者中正常化.
- 联合SRL和cabergoline治疗的效率似乎低于之前报告的效率.
- 对治疗疗效和患者选择的进一步研究是有必要的.
相关概念视频
Direct-Acting Cholinergic Agonists: Therapeutic Uses
744
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
744
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
323
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
323
Parkinson's Disease: Treatment
272
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
272
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.3K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.3K
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.2K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.2K
Drugs Acting on Autonomic Ganglia: Blockers
1.0K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.0K


